EWTX - Company ID 0001710072
The table below shows Edgewise Therapeutics, Inc.'s balance sheet line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & equivalents | $61.15M | $41.67M | $86.10M | $21.99M | $15.57M |
| Short-term investments | - | - | - | - | - |
| Receivables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Total current assets | $543.38M | $475.48M | $327.00M | $357.00M | $283.77M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Property, plant & equipment | $7.83M | $9.50M | $10.44M | $8.53M | $912.00K |
| Goodwill | - | - | - | - | - |
| Total assets | $552.60M | $486.82M | $340.04M | $367.10M | $285.23M |
| Accounts payable | $6.01M | $5.58M | $4.03M | $6.11M | $3.84M |
| Total current liabilities | $27.37M | $23.86M | $16.77M | $16.59M | $10.52M |
| Long-term debt | - | - | - | - | - |
| Total liabilities | $30.35M | $27.60M | $21.20M | $20.39M | $10.85M |
| Retained earnings | -$546.37M | -$378.58M | -$244.76M | -$144.60M | -$76.96M |
| Total equity | $522.26M | $459.22M | $318.83M | $346.72M | $274.38M |